Showing results (161-170 of 223) with videos related to

Sort By:
Pageof 23
Multiple Sclerosis Journal - Experimental, Translational and Clinical|April 7, 2018
Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosisSarah M Planchon, Karen T Lingas, Jane Reese Koç, et al.
Multiple Sclerosis and Related Disorders|March 17, 2023
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosisLana Zhovtis Ryerson, John F Foley, Gilles Defer, et al.
Neurology. Clinical Practice|June 24, 2022
Confirming a Historical Diagnosis of Multiple Sclerosis: Challenges and RecommendationsAndrew J Solomon, Georgina Arrambide, Wallace Brownlee, et al.
Neurology|October 14, 2016
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patientsGavin Giovannoni, Jeffrey A Cohen, Alasdair J Coles, et al.
The Lancet. Neurology|April 28, 2022
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trialJohn F Foley, Gilles Defer, Lana Zhovtis Ryerson, et al.
Annals of Clinical and Translational Neurology|March 27, 2026
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial ParticipantsRalf Gold, Krzysztof W Selmaj, Regina Berkovich, et al.
Stem Cells Translational Medicine|July 13, 2016
Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent MechanismAyal Rozenberg, Ayman Rezk, Marie-Noëlle Boivin, et al.
Multiple Sclerosis and Related Disorders|November 24, 2019
Technology-enabled comprehensive characterization of multiple sclerosis in clinical practiceLaura E Baldassari, Kunio Nakamura, Brandon P Moss, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2018
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II studyJeffrey A Cohen, Giancarlo Comi, Douglas L Arnold, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 24, 2022
Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendationsWallace J Brownlee, Christian Wolf, Hans-Peter Hartung, et al.
Pageof 23